Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance.
Marketed, Phase III, Phase l or ll, Pre-Clinical Stage
Men's Health, Oncology, Women's Health
106 New Bond Street
London, W1S 1DN
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.